- Thiery JP. Epithelial-mesenchymal transitions in development and pathology. Curr Opin Cell Biol 2003; 15:740-746
- Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev/Mol Cell Biol 2006; 7:131-142
- Lee JM et al. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biology 2006; 7:973-981
- Buck E et al. Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. Mol Cancer Ther. 2007; 6:532-541.
- Christfori C. New signals from an invasive front. Nature 2006; 41:444-450
- Brabletz T et al. Migrating cancer stem cells – an integrated concept of malignant tumor progression. Nature Rev 2005;5:744-749
- Thomson S et al. Epithelial-mesenchymal transition is a determinant in the sensitivity of non-small cell lung cancer cell lines to xenografts to epidermal growth factor inhibition. Cancer Res 2005;65(20):9455-9462
- Yauch RL et al. Epithelial versus mesenchymal phenotype determines in viro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 2005; 11(24); 8686-8698
- Larsson O et al. Role of insulin-like growth factor receptor signaling in cancer. Br J Cancer 2005; 92:2097-2101
- Samani AA et al. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev. 2007; 28(1): 20-47
- Buck E et al. Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity. Mol Cancer Ther 2006; 5(8):2051-2059
- Shaw RJ & Cantley LC .Ras, PI(3)K and mTOR signaling controls tumor cell growth. Nature 2006; 441:424-430
- Larue L & Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3’ kinase/AKT pathways. Oncogene 2005:24(50):7443-7454